Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Panakos

Cardiovascular Disease Boca Raton, FL Medical Doctor

NPI 1427491364 CMS profile 2781736

1000 Nw 9Th Ct Ste 101, Boca Raton, FL 33486

Open in the dashboard

General payments

$18,722

644 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$99,887 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Andrew Panakos of Boca Raton, FL is reported in the CMS Open Payments database as having received $18,722 across 644 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $99,887 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,158 115
2024 General $4,363 140
2023 General $3,790 102
2022 General $2,303 115
2021 General $2,852 127
2020 General $1,913 20
2019 General $1,344 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Panakos
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Andrew Panakos were reported at $2,158. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Andrew Panakos Cardiovascular Disease median Middle half National median
2019 $1,344 $450 $127–$1,392 $163
2020 $1,913 $242 $77–$751 $114
2021 $2,852 $335 $101–$1,037 $132
2022 $2,303 $395 $121–$1,211 $149
2023 $3,790 $443 $136–$1,283 $160
2024 $4,363 $450 $136–$1,323 $164
2025 $2,158 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,796 55 payments
  2. Penumbra, Inc. $1,701 7 payments
  3. Boston Scientific Corporation $1,384 15 payments
  4. Novartis Pharmaceuticals Corporation $1,142 152 payments
  5. Pfizer Inc. $1,035 50 payments
  6. AstraZeneca Pharmaceuticals LP $992 37 payments
  7. Medtronic Vascular, Inc. $797 15 payments
  8. Amgen Inc. $645 55 payments
  9. Merck Sharp & Dohme Corporation $604 32 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $521 20 payments
  11. Other $6,104 206 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,575 627 payments
  2. Travel and Lodging $2,541 5 payments
  3. Grant $1,105 3 payments
  4. Education $502 9 payments
Products named General payments · program years 2019–2025
  1. Indigo System $1,701 7 payments
  2. AVEIR Cardiac Rhythm Management $1,396 4 payments
  3. GENERAL - STRUCTURAL $1,105 3 payments
  4. FARXIGA $825 28 payments
  5. LEQVIO $815 123 payments
  6. VERQUVO $776 40 payments
  7. AVEIR Cardiac Rhythm Management $685 7 payments
  8. ELIQUIS $637 30 payments
  9. Repatha $566 50 payments
  10. XARELTO $465 28 payments
  11. Other $11,201 416 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,247

Median for Interventional Cardiology: 2,236

Drug cost

$794,405

Median for Interventional Cardiology: $380,412

Branded share of claims

33.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 413 $396,087
Repatha Sureclick Evolocumab Brand 90 $78,046
Entresto Sacubitril/Valsartan Brand 76 $77,734
Xarelto Rivaroxaban Brand 60 $71,838
Multaq Dronedarone Hcl Brand 35 $55,337
Jardiance Empagliflozin Brand 22 $21,071
Brilinta Ticagrelor Brand 27 $19,821
Farxiga Dapagliflozin Propanediol Brand 32 $19,333
Praluent Pen Alirocumab Brand 22 $10,501
Icosapent Ethyl Generic 14 $7,810

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$730,784

Of which drugs: $1,651

Medicare patients

1,936

Average age 79

Services billed

7,127

986 women, 950 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Arthritis 61%
Atrial fibrillation 41%
Diabetes 34%
Chronic kidney disease 34%
Heart failure 30%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 77 302 $1,651

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $200
$200 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $178
$178 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $172
$172 — —
ELIQUIS
  • PFIZER INC. $108
  • E.R. Squibb & Sons, L.L.C. $18
$125 413 —
NEXLETOL
  • Esperion Therapeutics, Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record